Predictors of adherence among Alzheimer's disease patients receiving oral therapy

References

• Alzheimer's Association. 2009 Alzheimer's Disease Facts and Figures. Alzheimers Dement 2009;5:234-70
   PubMed Web of Science ®Google Scholar
• Facts and Figures Alzheimer's disease: The Brain Killer. World Health Organization. Available at: http://searo.who.int/en/Section1174/Section1199/Section1567/Section1823_8066.htm [Last accessed 26 May 2009]
   Google Scholar
• Jonsson L. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease. Pharmacoeconomics 2003;21:1025-37
   PubMed Web of Science ®Google Scholar
• Hill J, Fillit H, Thomas SK, et al. Functional impairment, healthcare costs and the prevalence of institutionalization in patients with Alzheimer's disease and other dementias. Pharmacoeconomics 2006;24:265-80
   PubMed Web of Science ®Google Scholar
• National Institute on Aging. Progress Report on Alzheimer's Disease. Bethesda, MD, 1998
   Google Scholar
• Leon J, Neumann PJ. The cost of Alzheimer's disease in managed care: a cross-sectional study. Am J Manag Care 1999;5:867-77
   PubMed Web of Science ®Google Scholar
• Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, et al. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 2006;67:2186-91
   PubMed Web of Science ®Google Scholar
• Wang G, Cheng Q, Zhang S, et al. Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China. J Alzheimers Dis 2008;15:109-15
   PubMed Web of Science ®Google Scholar
• Beeri MS, Werner P, Adar Z, et al. Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord 2002;16:73-80
   PubMed Web of Science ®Google Scholar
• Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007;120:388-97
   PubMed Web of Science ®Google Scholar
• Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). National Institute for Health and Clinical Excellence (NICE). Available at: http://www.nice.org.uk/nicemedia/pdf/TA111fullversionamendedSept07.pdf [Last accessed 27 May 2009]
   Google Scholar
• Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71
   Web of Science ®Google Scholar
• Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract Suppl 2002;127:64-72
   PubMedGoogle Scholar
• Auriacombe S, Pere JJ, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129-38
   PubMed Web of Science ®Google Scholar
• Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer's disease – donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry 2002;17:288-89
   PubMed Web of Science ®Google Scholar
• Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of transdermal patch. Curr Med Res Opin 2007;23:2705-13
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45
   PubMed Web of Science ®Google Scholar
• Maddigan SL, Farris KB, Keating N, et al. Predictors of older adults’ capacity for medication management in a self-medication program: a retrospective chart review. J Aging Health 2003;15:332-52
   PubMed Web of Science ®Google Scholar
• Meyer ME, Schuna AA. Assessment of geriatric patients’ functional ability to take medication. DICP 1989;23:171-4
   PubMedGoogle Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease: Part II. treatment. Am Fam Physician 2002;65:2525-34
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995;273:1354-9
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-8
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
   PubMed Web of Science ®Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions; scientific review. JAMA 2002;288:2868-79
   PubMed Web of Science ®Google Scholar
• Van Wijk BLG, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005;23:2101-7
   PubMed Web of Science ®Google Scholar
• Ren XS, Kazis LE, Lee A, et al. Identifying patient and physician characteristics that affect compliance with antihypertensive medications. J Clin Pharm Ther 2002;27:47-56
   PubMed Web of Science ®Google Scholar
• Morris AB, Li J, Kroenke K, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy 2006;26:483-92
   PubMed Web of Science ®Google Scholar
• Benner JS, Pollack MF, Smith TW, et al. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health-Syst Pharm 2005;62:1468-75
   PubMed Web of Science ®Google Scholar
• Park DC, Hertzog C, Leventhal H, et al. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc 1999;47:172-83
   PubMed Web of Science ®Google Scholar
• Ownby RL, Hertzog C, Crocco E, et al. Factors related to medication adherence in memory disorder clinic patients. Aging Ment Health 2006;10:378-85
   PubMed Web of Science ®Google Scholar
• Wolff JL, Kasper JD. Caregivers of frail elders: updating a national profile. Gerontologist 2006;46:344-56
   PubMed Web of Science ®Google Scholar
• Piette JD, Heisler M. Problems due to medication costs among VA and non-VA patients with chronic illnesses. Am J Manag Care 2004;10:861-8
   PubMed Web of Science ®Google Scholar
• Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among Medicare beneficiaries. Health Aff (Millwood) 2003;22:220-9
   PubMed Web of Science ®Google Scholar
• Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil?. Alzheimer Dis Assoc Disord 2002;16:49-51
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Vergara J, Leon-Colombo T, et al. Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine. Rev Neurol 2006;43:449-53
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Paramore C, Lee WC, et al. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005;11:231-51
   PubMedGoogle Scholar
• Singh G, Thomas SK, Arcona S, et al. Treatment persistency with rivastigmine and donepezil in a large state Medicaid program. J Am Geriatr Soc 2005;53:1269-70
   PubMed Web of Science ®Google Scholar
• Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:485-91
   PubMed Web of Science ®Google Scholar
• Halpern R, Mody RR, Fuldeore MJ, et al. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009;25:1711-19
   PubMed Web of Science ®Google Scholar
• Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010;26:61-9
   PubMed Web of Science ®Google Scholar
• Gosselin A, Luo R, Lohoues H, et al. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health 2009;12:34-9
   PubMed Web of Science ®Google Scholar
• Pinsky BW, Takemoto SK, Lentine KL, et al. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant 2009;9:2597-606
   PubMed Web of Science ®Google Scholar
• Borah BJ, Huang X, Zarotsky V, et al. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009;25:1365-77
   PubMed Web of Science ®Google Scholar
• Halpern R, Barghout V, Zarotsky V, et al. Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. J Clin Outcomes Manag 2009;16:215-23
   Google Scholar
• Tseng C, Brook RH, Keeler E, et al. Impact of an annual dollar limit or “cap” on prescription drug benefits for Medicare patients. JAMA 2003;290:222-7
   PubMed Web of Science ®Google Scholar